Who Paid My Doc
Katie Obrien Paradis
Internal Medicine Oakes, ND Medical Doctor
NPI 1164689931 CMS profile 567078
1200 N 7Th St, Oakes, ND 58474
General payments
$234
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Katie Obrien Paradis of Oakes, ND is reported in the CMS Open Payments database as having received $234 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 45th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $216 | 1 | |
| 2021 | General | $19 | 1 |
Beside peers
- Katie Obrien Paradis
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Katie Obrien Paradis were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Katie Obrien Paradis | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $159 | $48–$570 | $163 |
| 2020 | $0 | $119 | $33–$402 | $114 |
| 2021 | $19 | $135 | $37–$521 | $132 |
| 2022 | $0 | $141 | $42–$496 | $149 |
| 2023 | $216 | $149 | $45–$519 | $160 |
| 2024 | $0 | $154 | $47–$537 | $164 |
| 2025 | $0 | $156 | $47–$551 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 143 drugsPart D claims
8,133
Drug cost
$533,921
Branded share of claims
22.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 129 | $78,975 | |
| Eliquis Apixaban | Brand | 127 | $78,005 | |
| Ozempic Semaglutide | Brand | 50 | $54,967 | |
| Xarelto Rivaroxaban | Brand | 91 | $53,590 | |
| Trulicity Dulaglutide | Brand | 41 | $38,784 | |
| Mounjaro Tirzepatide | Brand | 20 | $21,276 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 27 | $19,041 | |
| Rybelsus Semaglutide | Brand | 14 | $13,007 | |
| Entresto Sacubitril/Valsartan | Brand | 17 | $10,797 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 15 | $9,299 |
The 10 drugs with the highest cost, of 143 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in North Dakota
Related records
Internal Medicine in North Dakota
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in North Dakota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.